Search clinical trials for: ingenol disoxate gel 0.018%

Total 50 results

LEO Pharma

Terminated

A Trial to Compare the Incidence of Squamous Cell Carcinoma (SCC) and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp

Actinic Keratosis | Squamous Cell Carcinoma

United States, Spain, Canada, Germany, France, United Kingdom
LEO Pharma

Completed

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up

Actinic Keratosis

Germany
LEO Pharma

Completed

Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up

Actinic Keratosis

United States
Korea University
Samsung Medical Center; Asan Medical Center; Chonnam National University Hospital and other collaborators

Completed

Clinical Trial of Ingenol Mebutate Gel 0.015% & 0.05% in Actinic Keratosis

Actinic Keratosis

Korea, Republic of
LEO Pharma

Completed

A Simultaneous Treatment Regimen Compared to a Sequential Treatment Regimen With Ingenol Mebutate Gel 0.015% and 0.05% of Two Areas With Actinic Keratosis on Face/Scalp and Trunk/Extremities

Actinic Keratosis

Italy
University of California, San Francisco

Completed

Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients

Actinic Keratosis

United States
Peplin

Completed

A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)

Actinic Keratosis

United States, Australia
Skin Laser & Surgery Specialists
LEO Pharma

Completed

Clinical and Histologic Evaluation of Picato 0.15% Gel in the Cosmetic Improvement of Photoaged Skin

Actinic Keratosis | Photo-aged Skin
LEO Pharma

Completed

A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp

Actinic Keratosis

United States
LEO Pharma

Completed

PMS to Evaluate the Safety and Efficacy of Picato® Gel

Actinic Keratosis

Korea, Republic of
LEO Pharma

Completed

Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp

Actinic Keratosis

Canada, Germany, Australia, France, United Kingdom
Icahn School of Medicine at Mount Sinai
LEO Pharma

Completed

Ingenol Mebutate 0.015% Gel in the Treatment of Actinic Keratoses (AK) on the Face and Scalp

Actinic Keratosis

United States
Icahn School of Medicine at Mount Sinai
LEO Pharma

Completed

Treatment of Actinic Keratoses (AK) on the Face

Actinic Keratoses

United States
Peplin

Completed

A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations

Actinic Keratoses

United States, Australia
Goldman, Butterwick, Fitzpatrick and Groff
LEO Pharma

Completed

Evaluate the Efficacy and Safety of Large-Scale Field-Directed Topical Therapy of Actinic Keratosis of the Chest w/Ingenol Mebutate 0.015%

Actinic Keratosis

United States
Peplin

Completed

A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations

Actinic Keratoses

United States
LEO Pharma

Completed

Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis

Actinic Keratosis

United States
Instituto Nacional de Cancer, Brazil

Withdrawn

Evaluation of Ingenol Mebutate for Actinic Cheilitis Treatment (EIMAC)

Actinic Cheilitis
LEO Pharma

Completed

Histological Confirmation of Clinical Clearance of Actinic Keratoses Following Treatment With Ingenol Mebutate Gel, 0.05%

Actinic Keratosis

Australia, Germany
Peplin

Completed

A Study to Evaluate the Photoirritation Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers

Actinic Keratosis

United States
Peplin

Completed

Study to Evaluate the Safety and Efficacy of PEP005(Ingenol Mebutate) Gel, 0.05%, in Patients With Seborrhoeic Keratosis

Seborrheic Keratosis

Australia
Peplin

Completed

A Study to Evaluate the Photoallergic Potential of PEP005 (Ingenol Mebutate) Gel, 0.01% in Healthy Volunteers

Actinic Keratosis

United States
Peplin

Completed

Study to Evaluate the Safety and Efficacy of PEP005 (Ingenol Mebutate) Gel, 0.015%, in Patients With Photo-damaged Skin

Photo-damage

Australia
LEO Pharma

Completed

Pharmacokinetics of LEO 43204 Gel in Actinic Keratosis Administered Under Maximal Use Conditions

Actinic Keratosis

United States
Peplin

Completed

A Study to Evaluate the Pharmacokinetics of PEP005 (Ingenol Mebutate) Gel, 0.05%, When Applied in a Maximal Use Setting to the Dorsal Aspect of the Forearm in Patients With Actinic Keratosis

Actinic Keratosis

United States
LEO Pharma

Completed

PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Histology

Actinic Keratosis

Germany
LEO Pharma

Completed

PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy

Actinic Keratosis

Germany
Icahn School of Medicine at Mount Sinai
LEO Pharma

Completed

Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses

Actinic Keratoses

United States
Neal D. Bhatia, MD
LEO Pharma

Completed

Exploratory Study of Efficacy and Safety of Ingenol Mebutate 0.05% Gel for Common Warts on the Hands.

Verruca Vulgaris | Common Warts

United States
Padagis LLC

Completed

To Compare Safety and Efficacy of Perrigo's Drug Product Compared to an FDA Approved Drug Product in the Treatment of Actinic Keratosis

Actinic Keratosis
Padagis LLC

Completed

To Compare Safety and Efficacy of Perrigo's Drug Compared to an FDA Approved Drug in the Treatment of Actinic Keratosis

Actinic Keratosis
Peplin

Completed

Study to Determine the Sensitizing Potential of PEP005 Topical Gel in Healthy Volunteers Using a Repeat Insult Patch Test Design

Healthy

United States
Peplin

Completed

PEP005 Gel - Evaluation of the Safety and Efficacy of Ingenol Mebutate Gel on a Superficial Basal Cell Carcinoma on the Trunk or Extremities

Superficial Basal Cell Carcinoma

Australia
LEO Pharma

Completed

Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%

Actinic Keratosis (AK)

Germany, United Kingdom, France
Pacific Dermaesthetics
LEO Pharma

Unknown

Ingenol Mebutate (Picato®) With Methyl Aminolevulinate Photodynamic Therapy for the Treatment of Actinic Keratosis

Actinic Keratosis
Eisai Limited

Completed

A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

Germany
LEO Pharma

Completed

Safety and Dose Finding Study of New Vehicle Formulations Containing Ingenol Mebutate to Treat Actinic Keratosis on the Forearm

Actinic Keratosis

Australia
LEO Pharma

Completed

Efficacy and Safety of Ingenol Mebutate Gel 0.015% Compared to Diclofenac Sodium Gel 3% in Subjects With Actinic Keratoses on the Face or Scalp

Actinic Keratosis (AK)

Germany
Mayo Clinic
Actelion

Completed

Valchlor in the Treatment of Lichen Planopilaris

Lichen Planopilaris

United States
Horus Pharma

Unknown

Evaluation of Efficacy and Safety of Vismed Gel Multi 0.3% Versus Vismed Multi 0.18% on Treatment of Ocular Dryness

Dry Eye
University of Copenhagen

Completed

Neurogenic Mechanisms in Burning Mouth Syndrome (BMS17)

Burning Mouth Syndrome

Denmark
Thomas Jefferson University
Actelion

Unknown

Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides

Mycosis Fungoides | Cutaneous T-cell Lymphoma
University of Utah

Active, not recruiting

Pharmacokinetics of Atropine Oral Gel

Cerebral Palsy | Sialorrhea

United States
American Scitech International
Johnson & Johnson

Unknown

Efficacy of R-Pdf/Gbb in Healing Wounds Caused by Third Degree Thermal and Electrical Burns

Burns | Electric Burns

United States
Rochester Skin Lymphoma Medical Group, PLLC
Rochester General Hospital

Completed

Mechlorethamine Induced Contact Dermatitis Avoidance Study (MIDAS)

Mycosis Fungoides | Cutaneous T-cell Lymphoma | Transformed Mycosis Fungoides | Cutaneous T-cell Lymphoma Stage I | Folliculotropic Mycosis Fungoides | Granulomatous Slack Skin | Syringotropic Mycosis Fungoides | Mycosis Fungoides Variant

United States
Galderma R&D

Completed

Systemic Bioavailability Study Of Col-118 Administered Topically as a 0.18 % Facial Gel And Brimonidine Ophthalmic Solution 0.2%

Erythematous Rosacea

United States
University Hospital, Grenoble

Completed

Pulmonary Nodule Detection: Comparison of an Ultra Low Dose vs Standard Scan. (npUBD)

Smoking | Lung Cancer | Radiation Exposure

France
Leiden University Medical Center
Erasmus Medical Center

Recruiting

Vascular Signature Mapping of Brain Tumor Genotypes (VASIM)

Glioma

Netherlands
Aston University
University of Worcester

Completed

Non-Pharmaceutical Treatment of Seasonal Allergic Conjunctivitis

Hypersensitivity

United Kingdom
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Calaspargase Pegol or Pegaspargase and Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia | Adult B Acute Lymphoblastic Leukemia | Childhood B Acute Lymphoblastic Leukemia

United States

3

Subscribe